FDA Greenlights Initial Test for Identifying Possible Opioid Addiction Risk
On December 21, 2023, the FDA granted approval for the inaugural DNA-based test aimed at gauging an individual’s susceptibility to opioid addiction. Known as AvertD, this prescription-only test is specifically designed for pre-assessment before administering orally consumed opioids for acute pain, especially prior to scheduled surgeries. Targeting adults without a history of oral opioid painkiller…